The noncorneal route in ocular drug delivery

Ophthalmic Drug Delivery Systems, Second Edition, Revised and Expanded

Volumn , Issue , 2003, Pages 335-363

  Ahmed, Imran ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85058108852     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (154)

1. McCartney, H. J., Drysdale, I. O., Gornall, A. G., and Basau, P. K. (1965). An auto-radiographic study of the penetration of subconjunctivally injected hydrocortisone into the normal and inflamed rabbit eyes, Invest. Ophthalmol., 4: 297.
2. Bienfang, D. C. (1973). Sector pupillary dilation with an epinephrine strip, Am. J. Ophthalmol., 75: 883.
3. Doane, M. G., Jensen, A. D., and Dohlman, C. H. (1978). Penetration routes of topically applied eye medications, Am. J. Ophthalmol., 85: 383-386.
4. Bito, L. Z., and Baroody, R. A. (1981). The penetration of exogenous prostaglandin and arachidonic acid into, and their distribution within, the mammalian eye, Curr. Eye Res., 1: 659-669.
5. Ahmed, I., and Patton, T. F. (1985). Importance of the noncorneal absorption route in topical ophthalmic drug delivery, Invest. Ophthal. Vis. Sci., 26: 584-587.
6. Ahmed, I., and Patton, T. F. (1987). Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption, Int. J. Pharm., 38: 9-21.
7. Urtti, A., Sondo, T., Pipkin, J. D., Rork, G., and Repta, A. J. (1988). Application site dependent ocular absorption of timolol, J. Ocul. Pharmacol., 4: 335-343.
8. Ashton, P., and Lee, V. H. L. (1989). Role of drug lipophilicity in determining the contribution of noncorneal penetration in ocular drug absorption, Pharm. Re., 6: S114.
9. Lee, V. H. L., Ashton, P., Bundgaard, H., and Heuer, D. K. (1990). Noncorneal route of drug penetration role of drug lipophilicity in determining its contribution to the ocular absorption of beta blockers and timolol prodrugs, Invest. Ophthal. Vis. Sci., 31: 403.
10. Chien, D.-S., Homsy, J. J., Gluchowski, C., and Tang-Liu, D. (1990). Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes, Curr. Eye Res., 9: 1051-1059.
11. Sasaki, H., Ichikawa, M., Kawakami, S., Yamamura, K., Nishida, K., and Nakamura, J. (1996). In situ ocular absorption of tilisolol through ocular membranes in albino rabbits, J. Pharm. Sci., 85: 940-943.
12. Rabiah, P. K., Fiscella, R. G., and Tessler, H. H. (1996). Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis, Invest. Ophthal. Vis. Sci., 37: 613-618.
13. Kurmala, P., Wilson, G. C., Foulds, W. S., Dhillon, B., Kamal, A., and Rao, L. S. (1997). Suprachoroidal route of drug delivery to the posterior segment of the eye, J. Pharm. Pharmacol., 49: 83.
14. Worakul, N., and Robinson, J. R. (1997). Review: Ocular pharmacokinetics/pharmacodynamics, Eur. J. Pharm. Biopharm., 44: 71-83.
15. Schoenwald, R. D., Deshpande, G. S., Rethwisch, D. G., and Barfknecht, C. F. (1997). Penetration into the anterior chamber via the conjunctival/scleral pathway, J. Ocul. Pharmacol. Therap., 13: 41-59.
16. Sasaki, H., Icikawa, M., Kawakami, S., Yamamura, K., and Mukai, T. (1997). In situ ocular absorption of ophthalmic b-blockers through ocular membranes in albino rabbits, J. Pharm. Pharmacol., 49: 140-144.
17. Conroy, C. W., and Maren, T. H. (1998). The ocular distribution of metha-zolamide after corneal and sclera administration: Effect of ionization state, J. Ocul. Pharmacol. Therap., 14: 565-573.
18. Pech, B., Chetoni, P., Saettone, M. F., Duval, O., and Benoit, J.-P. (1993). Preliminary evaluation of a series of amphiphilic timolol prodrugs: Possible evidence for transscleral absorption, J. Ocular Pharmacol., 9: 141-150.
19. Chien, D. S., TangLiu, D. D. S., and Woodward, D. F. (1997). Ocular penetration and bioconversion of prostaglandin F2 alpha prodrugs in rabbit cornea and conjunctiva, J. Pharm. Sci., 86: 1180-1186.
20. Romanelli, L., Valeri, P., Morrone, L. A., Pimpinella, G., Graziani, G., and Tita, B. (1994). Ocular absorption and distribution of bendazac after topical administration to rabbits with different vehicles, Life Sci., 54: 877-885.
21. Lehr, C. M., Lee, Y.-H., and Lee, V. H. L. (1992). Effect of mucoadhesive polymer polycarbophil on ocular penetration of gentamicin, Pharm. Weekbl. Sci. Ed., 14: F31.
22. Shiue, M. H. I., Kim, K. J., and Lee, V. H. L. (1998). Modulation of chloride secretion across the pigmented rabbit conjunctiva, Curr. Eye. Res., 14: 927-935.
23. Ahmed, I., and Patton, T. F. (1986). Selective intraocular delivery of liposome-encapsulated inulin via the non-corneal absorption route, Int. J. Pharm., 34: 163-167.
24. Prausnitz, M. R., and Noonan, J. S. (1998). Permeability of the cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye, J. Pharm. Sci., 87: 1479-1488.
25. Lee, V. H. L., Carson, L. W., and Takemoto, K. A. (1986). Macromolecular drug absorption in the albino rabbit eye, Int. J. Pharm., 29: 43-51.
26. Ashton, P., Lee, V. H. L. (1989). Para- and transcellular pathways of drug penetration across the cornea and conjunctiva of the pigmented rabbit, Pharm. Res., 6: S590.
27. Huang, A. J. W., Tseng, S. C. G., and Kenyon, K. R. (1990). Paracellular permeability of corneal and conjunctival epithelia, Invest. Ophthalmol. Vis. Sci., 30: 684-689.
28. Kahn, M., Barney, N. P., Briggs, R. M., Bloch, K. J., and Allansmith, M. R. (1990). Penetrating the conjunctival barrier: The role of molecular weight, Invest. Ophthalmol. Vis. Sci., 31: 258-261.
29. Hamalainen, K. M., Kananen, K., Auriola, S., Kontturi, K., and Urtti, A. (1997). Characterization of paracellular and aqueous penetration routes in cornea, conjunctival and sclera, Invest. Ophthal. Vis. Sci., 38: 627-634.
30. Hamalainen, K. M. (1997). Characterization of the paracellular penetration route-reply, Invest. Ophthal. Vis. Sci., 38: 2179-2180.
31. Horibe, Y., Hosoya, K., Kim, K. J., Ogiso, T., and Lee, V. H. L. (1997). Polar solute transport across the pigmented rabbit conjunctiva: size dependence and the influence of 8-bromo cyclic ademosine monophosphate, Pharm. Res., 14: 1246-1251.
32. Maurice, D. M. (1997). Letter: Characterization of paracellular penetration routes, Invest. Ophthalmol. Vis. Sci., 38: 2177-2179.
33. Kompella, U., Kim, K. J., and Lee, V. H. L. (1992). Active ion and nutrient transport mechanisms of the pigmented rabbit conjunctiva, Pharm. Res., 9(Suppl. 3).
34. Kompella, U., Kim, K. J., and Lee, V. H. L. (1993). Active chloride transport in the pigmented rabbit conjunctiva, Curr. Eye Res., 12: 1041-1048.
35. Kompella, U., Kim, K. J., and Lee, V. H. L. (1995). Possible existence of Na + coupled amino acid transport in the pigmented rabbit conjunctiva, Life Sci., 57: 1427-1431.
36. Lee, V. H. L. (1996). Ocular epithelial models, Pharm Biotech., 8: 425-436.
37. Kompella, U. B., and Lee, V. H. L. (1998). Barriers to drug transport in the ocular epithelia, in Transport Processes in Pharmaceutical Systems (G. L. Amidon, P. I. Lee, and E. M. Topp, eds.), Marcel Dekker, New York, pp. 317-375.
38. Bill, A. (1965). Movement of albumin and dextran through the sclera, Arch. Ophthalmol., 74: 248-252.
39. Maurice, D. M., and Polgar, J. (1977). Diffusion across the sclera, Exp. Eye. Re., 25: 577-582.
40. Ahmed, I., Gokhale, R. D., Shah, M. V., and Pattom, T. F. (1987). Physicochemical determinants of drug diffusion across the conjunctiva, sclera and cornea, J. Pharm. Sci., 76: 583-586.
41. Edelhauser, H. F., and Maren, T. H. (1988). Permeability of the human cornea and sclera to sulfonamide carbonic anhydrase inhibitors, Arch. Ophthalmol., 106: 1110-1115.
42. Olsen, T. W., Edelhauser, H. F., Lim, J. I., and Geroski, D. H. (1995). Human scleral permeability: effects of age, cryotherapy, transscleral diode laser and surgical thinning, Invest. Ophthalmol. Vis. Sci., 36: 1893-1903.
43. Prausnitz, M. R., Edwards, A., Noonan, J. S., Rudnick, D. E., Edelhauser, H. F., and Geroski, D. H. (1998). Measurement and prediction of transient transport across the sclera for drug delivery to the eye, Ind. Eng. Chem. Res., 37: 2903-2907.
44. Edwards, A., and Prausnitz, M. R. (1998). Fiber matrix model of sclera and corneal stroma for drug delivery to the eye, AIChE J., 44: 214-225.
45. Unlu, N., and Robinson, J. R. (1998). Scleral permeability to hydrocortisone and mannitol in the albino rabbit eye, J. Ocul. Pharm. Ther., 14: 273-281.
46. Rudnick, D. E., Noonan, J. S., Geroski, D. H., Praunitz, M. R., and Edelhuser, H. F. (1999). The effect of intraocular pressure on human and scleral permeability, Invest. Ophthal. Vis. Sci., 40: 3054-3058.
47. Ambati, J., Canakis, C. S., Miller, J. W., Gragoudas, E. S., Edward, A., Weissgold, D. J., Kim, I., Delor, F. C., and Adamis, A. P. (2000). Diffusion of high molecular weight compounds through the sclera, Invest. Ophthal. Vis. Sc., 41: 1181-1185.
48. Maurice, D. M. (1973). Electrical potential and ion transport, Exp. Eye Res., 15: 527-532.
49. Sorensen, T., and Jensen, F. T. (1979). Conjunctival transport of technetium-99m pertechnetate, Acta Opthalmol., 57: 691-699.
50. Sasaki, H., Chien, D. S., and Lee, V. H. L. (1988). Differential conjunctival and corneal permeability to beta-blockers and its influence on the ratio of systemic to ocular drug absorption, Pharm. Res., 5: S98.
51. Wang, W., Sasaki, H., Chien, D.-S., and Lee, V. H. L. (1991). Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: A comparison with corneal penetration, Curr. Eye. Res., 10: 571-579.
52. Sasaki, H., Igarashi, Y., Nagano, T., Yamamura, K., Nishida, K., and Nakamura, J. (1995). Penetration of beta-blockers through ocular membranes in albino rabbits, J. Pharm. Pharmacol., 47: 17-21.
53. Sasaki, H., Icikawa, M., Yamamura, K., Nishida, K., and Nakamura, J. (1997). Ocular membrane permeability of hydrophilic drugs for ocular peptide delivery, J. Pharm. Pharmacol., 49: 135-139.
54. Sasaki, H., Masataka, I., Shigeru, K., Keno, Y., Takahiro, M., Koyo, N., and Junzo, N. (1997). Ocular absorption of ophthalmic beta-blockers through ocular membranes in albino rabbits, J. Pharm. Pharmacol., 49: 140-144.
55. Alm, A., and Bill, A. (1973). The effect of pilocarpine and neostigmine on blood flow through the anterior uvea in monkeys. A study with radiolabelled microspheres, Exp. Eye. Re., 15: 31-36.
56. Green, K., Wynn, H., and Padgett, D. (1978). Effects of 9-Tetrahydrocannabinol on ocular blood flow and aqueous humor formation, Exp. Eye Res., 26: 65-69.
57. Riva, C. E., and Ben-Sira, I. (1974). Injection method for ocular hemodynamic studies in man, Invest. Ophthalmol., 13: 77-79.
58. Lee, V. H. L., and Robinson, J. R. (1979). Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits, J. Pharm. Sci., 68: 673.
59. Bill, A., Tornquist, P., and Alm, A. (1980). Permeability of the intraocular blood vessels, Trans. Ophthalmol. Soc. U.K., 100: 332-336.
60. Lee, V. H. L., Takemoto, K. A., and Iimoto, D. S. (1984). Precorneal factors influencing the ocular distribution of topically applied inulin, Curr. Eye Res., 3: 585-592.
61. Ziada, G., El-Haddad, S., Fatouh, M., Mustafa, H., and Mahfouz, M. (1985). Radionuclide study of the blood ocular barrier, Eur. J. Drug Met. Pharmacokin., 10: 325-328.
62. Chang, S.-C., and Lee, V. H. L. (1987). Nasal and conjunctival contribution to the systemic absorption of topical timolol in the pigmented rabbit implications in the design of strategies to maximize the ratio of ocular to systemic absorption, J. Ocul. Pharmacol., 3: 159-170.
63. Maitani, Y., Yamamoto, T., Takayama, K., Peppas, N. A., and Nagai, T. (1995). A modelling analysis of drug absorption and administration from ocular, nasolacrimal duct, and nasal routes, Int. J. Pharm., 126: 89-94.
64. Yoshi, M., Nagai, T., Kollias, K., and Peppas, N. (1997). Design of ocular/lacrimal and nasal systems through analysis of drug administration and absorption, J. Contr. Rel., 49: 185-192.
65. Cunha-Vaz, J. G. (1997). The blood-ocular barriers: Past, present, and future, Doc. Ophthalmol. 93: 149-157.
66. Kyyronen, K., and Urtti, A. (1990). Improved ocular-systemic absorption ratio of timolol by viscous vehicle and phenylephrine, Invest. Ophthal. Vis. Sc., 31: 1827-1833.
67. Kyyronen, K., and Urtti, A., (1990). Effects of epinephrine pretreatment and solution pH on ocular and systemic absorption of ocularly applied timolol in rabbits, J. Pharm. Sci., 79: 688-691.
68. Finne, U., Vaisanen, V., and Urtti, A. (1990). Modification of ocular and systemic absorption of timolol from ocular inserts by a buffering agent and a vasoconstrictor, Int. J. Pharm., 65: 19-27.
69. Ohdo, S., Grass, G. M., and Lee, V. H. L. (1991). Improving the ocular to systemic ratio of topical timolol by varying the dosing time, Invest. Ophthal. Vis. Sc., 32: 2790-2798.
70. Jarvinen, K., Vartianen, E., and Urtti, A. (1992). Optimizing the systemic and ocular absorption of timolol from eye drops, STP Pharma Sci., 2: 105-110.
71. Urtti, A., and Salminen, L. (1993). Review: Minimizing systemic absorption of topically administered ophthalmic drugs, Surv. Ophthalmol., 37: 435-456.
72. Lee, Y.-H., and Lee, V. H. L. (1993). Formulation influence on ocular and systemic absorption of topically applied atenolol in the pigmented rabbit, J. Ocular Pharmacol., 9: 47-58.
73. Urtti, A. (1994). Delivery of antiglaucoma drugs: ocular versus systemic absorption, J. Ocul. Pharmacol., 10: 349-357.
74. Jones, A. L., Keighley, J. E., Gold, W., and Good, A. M. (1996). Review: eye drops-the hidden poison, Scott. Med.J., 41: 110-112.
75. Jay, W. M., Aziz, M. J., and Green, K. (1985). The effect of retrobulbar epinephrine injection on ocular and optic nerve blood flow, Curr. Eye. Res., 4: 55-58.
76. Chast, F., Bardin, C., Sauvageon-Martre, H., Callaert, S., and Chaumeil, J. C. (1991). Systemic morphine pharmacokinetics after ocular administration, J. Pharm. Sci., 80: 911-917.
77. Losa, C., Alonson, M. J., Vila, J. L., Orallo, F., Martinez, J., Saavedra, J. A., and Pastor, J. C. (1992). Reduction of cardiovascular side-effects associated with ocular administration of metipranolol by inclusion in polymeric nanocapsules, J. Ocul. Pharmacol., 8: 191-198.
78. Li, B. H. P., and Chiou, G. C. Y. (1992). Systemic administration of calcitonin through the ocular route, Life Sci., 50: 349-354.
79. Chiou, G. C. Y., Shen, Z. F., Zheng, Y. Q., and Chen, Y. J. (1992). Enhancement of systemic delivery of peptide drugs via the ocular route with surfactants, Drug Dev. Res., 27: 177-183.
80. Harris, D., Liaw, J. H., and Robinson, J. R. (1992). Routes of delivery: case studies. (7). Ocular delivery of peptide and protein drugs, Adv. Drug Delivery Rev., 8: 331-339.
81. Chiou, G. C. Y. (1994). Systemic delivery of polypeptide drugs through ocular route, J. Ocul. Pharmacol., 10: 93-99.
82. Morgan, R. V. (1995). Delivery of systemic regular insulin via the ocular route in cats, J. Ocul. Pharmacol. Ther., 11: 565-573.
83. Morgan, R. V., and Huntzicker, M. A. (1996). Delivery of systemic regular insulin via the ocular route in dogs, J. Ocul. Pharmacol. Ther., 12: 515-526.
84. Friedrich, S. W., Saville, B. A., Cheng, Y.-L., and Rootman, D. S. (1996). Pharmacokinetic differences between ocular inserts and eye drops, J. Ocul. Pharmacol., 12: 5-18.
85. Lee, Y. C., and Yalkowski, S. H. (1999). Effect of formulation on the systemic absorption of insulin from enhancer-free ocular device, Int. J. Pharm., 185: 199-204.
86. Mishima, S. (1981). Clinical pharmacokinetics of the eye, Invest. Ophthalmol. Vis. Sc., 21: 504-541.
87. Shell, J. W. (1982). Pharmacokinetics of topically applied ophthalmic drugs, Surv. Ophthalmol., 26: 207-218.
88. Mikkelson, T. J. (1984). Review: Ophthalmic drug delivery, Pharm. Tech., 8: 90-98.
89. Lee, V. H. L. (1985). Review: Topical ocular drug delivery-recent advances and future perspectives, Pharm. Int., 6: 135-138.
90. Lee, V. H. L., and Robinson, J. R. (1986). Review: Topical ocular drug delivery: Recent developments and future challenges, J. Ocul. Pharmacol., 2: 67-108.
91. Schoenwald, R. D. (1990). Review: Ocular drug delivery-Pharmacokinetic considerations, Clin. Pharmacokin., 18: 255-269.
92. Lee, V. H. L. (1990). Review: New directions in the optimization of ocular drug delivery, J. Ocul. Pharmacol., 6: 157-164.
93. Ding, S. (1998). Review: Recent advances in ophthalmic drug delivery, Pharm. Sci. Technol. Today., 1: 328-335.
94. Boutlais, C. L., Acar, L., Zia, H., Sado, P. A., Needham, T., and Leverge, R. (1998). Ophthalmic drug delivery systems-recent advances, Prog. Retinal Eye Re., 17: 33-58.
95. Robinson, J. C. (1993). Ocular anatomy and physiology relevant to ocular drug delivery.Drugs Pharm. Sci., 58: 29-57.
96. Hosoya, K., and Lee, V. H. L. (1997). Cidofovir transport in the pigmented rabbit conjunctiva, Curr. Eye Res., 16: 693-697.
97. Mishima, S., Gasset, A., Klyce, S. D., and Baum, J. L. (1966). Determination of the tear volume and tear flow, Invest. Ophthalmol., 5: 264-276.
98. Maurice, D. M. (1967). The use of fluorescein in ophthalmic research, Invest. Ophthalmol., 6: 464.
99. Holly, F. J. (1973). Formation and stability of the tear film, Int. Ophthalmol. Clin., 13: 73.
100. Pfister, R. R. (1975). The normal surface of the conjunctival epithelium: A scanning electron microscopic study, Invest. Ophthalmol., 14: 267.
101. Kessing, S. V. (1968). Mucus gland system of the conjunctiva, Acta Ophthalmol. (Suppl.., 95: 133.
102. Nichols, B., Davson, C. R., and Togni, B. (1983). Surface features of the conjunctiva and cornea, Invest. Ophthalmol. Vis. Sci., 24: 570-576.
103. Watsky, M. A., Jablonski, M. M., and Edelhauser, H. F. (1988). Comparison of conjunctival and corneal surface areas in rabbit and human, Curr. Eye Res., 7: 483-486.
104. Ehlers, N. (1965). On the size of the conjunctival sac, Acta Ophthalmol., 43: 205-210.
105. Maurice, D. M. (1984). The cornea and sclera in The Eye(H. Davson, ed.), Academic Press, New York, pp. 1-158.
106. Battagliolo, J. L., and Kamm, R. D. (1984). Measurements of the compressive properties of scleral tissue, Invest. Ophthalmol. Vis. Sci., 25: 59-65.
107. Olsen, T. W., Aaberg, S. Y., Geroski, D. H., Edelhauser, H. F. (1998). Human sclera: thickness and surface area, Am. J. Ophthalmol., 125: 237-241.
108. Keeley, F. W., Morin, J. D., and Vesely, S. (1984). Characterization of collagen from normal human sclera, Exp. Eye Res., 39: 533-542.
109. Kleinstein, R. N., and Fatt, I. (1977). Pressure dependency of transscleral flow, Exp. Eye Res., 24: 335-340.
110. Francoeur, M., and Patton, T. F. (1979). Kinetics of corneal drug up-take studied by corneal perfusion in situ I. Evaluation of system and up-take of ethyl p-aminobenzoate in rabbits, Int. J. Pharmaceut., 2: 337-342.
111. Olejnik, O., Davis, S. S., and Wilson, C. G. (1981). A non-invasive perfusion technique for measuring the corneal permeation of drugs, J. Pharm. Pharmacol.
112. Krohn, D. L., and Breitfeller, J. M. (1974). Transport of pilocarpine by isolated cornea, Invest. Ophthalmol., 13: 312-316.
113. Gegge, H. S., and Gipson, I. K. (1985). Removal of viable sheets of conjunctival epithelium with dipase II, Invest. Ophthalmol. Vis. Sci., 26: 15-22.
114. Saha, P., Kim, K. J., and Lee, V. H. L. (1996). A primary culture model of rabbit conjunctival epithelial cells exhibiting tight barrier properties, Curr. Eye. Res., 15: 1163-1169.
115. Goskonde, V. R., Khan, M. A., Hutak, C. M., and Reddy, I. K. (1999). Permeability characteristics of novel mydriatic agents using an in vitro cell culture model that utilizes sirc rabbit corneal cells, J. Pharm. Sci., 88: 180-184.
116. Yang, J. J., Ueda, H., Kim, K. J., and Lee, V. H. L. (2000). Meeting future challenges in topical ocular drug delivery: Development of an air interfaced primary culture of rabbit conjunctival epithelial cells on a permeable support for drug transport studies, J. Contr. Rel., 65: 1-11.
117. Sasaki, H., Igarashi, Y., Nishida, K., and Nakamura, J. (1994). Intestinal permeability of ophthalmic beta-blockers for predicting ocular permeability, J. Pharm. Sci., 83: 1335-1338.
118. Zhu, Y. P., Wilson, W. S. (1996). An ex vivo model for the assessment of drug delivery to the eye: isolated bovine perfusion system, Eur. J. Pharm. Biopharm., 42: 405-410.
119. Kunou, N., Ogura, Y., Honda, Y., Hyon, S. H., and Ikada, Y. (2000). Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate, J. Biomed. Mat. Res., 51: 634-641.
120. Foroutan, S. M., and Watson, D. G. (1999). In vitro evaluation of polyethylene glycol esters of hydrocortisone esters of hydrocortisone 21-succinate as ocular prodrugs, Int. J. Pharm., 182: 79-92.
121. Sasaki, H., Igarashi, Y., Nishida, K., and Nakamura, J. (1993). Ocular delivery of the beta-blocker, tilisolol, through the prodrug approach, Int. J. Pharm., 93: 49-60.
122. Hamalainen, K. M., Ranta, V. P., Auriola, S., and Urtti, A. (2000). Enzymatic and permeation barrier of [D-ala (2)]-met-enkephalinamide in the anterior membranes of the albino rabbit eye, Eur. J. Pharm. Sci., 9: 265-270.
123. Madhu, C., Rix, P., Nguyen, T., Chien, D. S., Woodward, D. F., and TangLiu, D. D. S. (1998). Penetration of natural prostaglandins and their ester prodrugs and analogs across human ocular tissues in vitro, J. Ocul. Pharm. Ther., 14: 389-399.
124. Sasaki, H., Nagano, T., Yamamura, K., Nishida, K., and Nakamura, J. (1995). Ophthalmic preservatives as absorption promoters for ocular drug delivery, J. Pharm. Pharmacol., 47: 703-707.
125. Sasaki, H., Yamamura, K., Tei, C., Nishida, K., and Nakamura, J. (1995). Ocular permeability of FITC-dextran with absorption promoter for ocular delivery of peptide drugs, J. Drug Targetin., 3: 129-135.
126. Chung, Y. B., Nishiura, A., and Lee, V. H. L. (1993). Pz-peptide as a novel enhancer of ocular epithelial paracellular permeability in the rabbit, Pharm. Re., 10: 204.
127. Bok, C. Y., Kun, H., Akio, N., and Lee, V. H. L. (1998). Ocular absorption of pz-peptide and its effect on the ocular systemic pharmacokinetics of topically applied drugs in the rabbit, Pharm. Res., 15: 1882-1887.
128. Peyman, G. A., and Ganiban, G. J. (1995). Delivery systems for intraocular routes, Adv. Drug Delivery Rev., 16: 107-123.
129. Geroski, D. H., and Edelhauser, H. F. (2000). Review: Drug delivery for posterior segment eye disease, Invest. Ophthal. Vis. Sci.: 961-964.
130. Coltrust, M. J., Williams, R. L., Hiscott, P. S., and Grierson, I. (2000). Review: Biomaterials used in posterior segment of the eye, Biomaterials., 21: 649-665.
131. Peyman, G. A., and Ganiban, G. J. (1995). Review: Delivery systems for intraocular routes, Adv. Drug Delivery Rev., 16: 107-123.
132. Velez, G., and Whitcup, S. M. (1999). New developments in sustained release drug delivery for the treatment of intraocular disease, Br. J. Ophthalmol., 83: 1225-1229.
133. Conroy, C. W. (1997). Sulfonamides do not reach the retina in therapeutic amounts after topical application to the cornea, J. Ocul. Pharmacol., 13: 465-472.
134. Lim, J. I., Maguire, A. M., John, G., Mohler, M. A., and Fiscella, R. G. (1993). Intraocular tissue plasminogen-activator concentrations after subconjunctival delivery, Ophthalmolog., 100: 373-376.
135. Pakes, S. P. (1998). V. A., Grant: Implantation of a sub-tenon drug delivery device loaded with a test article in rabbits and distribution of the test article in ocular tissues. Dept. of Veterans Administration Grant, 1998.
136. Adamis, A. P., Gragoudas, E. S., and Miller, J. W. (1999). Patent: Targeted trans-scleral controlled release drug delivery to the retina and choroid, WO 2000US207.
137. Sasaki, H., Kashiwagi, S., Mukai, T., Nishida, K., Nakamura, J., Nakashima, M., and Ichikawa, M. (1999). Drug absorption behavior after periocular injections, Biol. Pharm. Bull., 22: 956-960.
138. Blair, J. M., Gionfriddo, J. R., Polazzi, L. M., Sojka, J. E., Pfaff, A. M., and Bingaman, D. P. (1999). Subconjunctivally implanted micro-osmotic pumps for continuous ocular treatment in forses, Am. J. Vet. Res., 60: 1102-1105.
139. LaFranco, D. M., Tao, T. V., Yan, G. C., and Herbert, C. P. (1999). Posterior sub-Tenon’s steroid injection for the treatment of posterior ocular inflammation: Indications, efficacy and side-effects, Graefe’s Arch. Clin. Exp. Ophthal., 237: 289-295.
140. Kunow, N., Ogura, Y., Honda, Y., Hyon, S. H., and Ikada, Y. (2000). Biodegradable sclera implant for controlled intraocular delivery of betamethasone phosphate, J. Biomed. Res., 51: 635-641.
141. Schulman, J. A., Peyman, G. A., and Liu, J. (1987). The intraocular penetration of acyclovir after subconjunctival administration, Ophthal. Surg., 18: 111-114.
142. Kurmala, P., Wilson, C. G., Dhillon, B., Kamal, A., and Rao, L. S. (1997). A comparison of intraocular delivery routes for an acyclovir implant using an arterially perfused sheep eye, Pharm. Res., 14: S46.
143. Callegan, M. C., Mobden, J. A., O’Callaghan, R. J., and Hill, J. M. (1995). Ocular drug delivery: A comparison of transcorneal iontophoresis to corneal collagen shields, Int. J. Pharm., 123: 173-179.
144. Sarraf, D., and Lee, D. A. (1994). Review: The role of iontophoresis in ocular drug delivery, J. Ocul. Pharmacol., 10: 69-81.
145. Frucht, P. J., Solomon, A., Doron, R., Ever-Hadani, P., Manor, O., and Shapiro, M. (1996). Efficacy of iontophoresis in the rat cornea, Graefe’s Arch. Clin. Exp. Ophthal., 234: 765-769.
146. Friedberg, M. L., Pleyer, U., and Mondino, B. J. (1991). Device drug delivery to the eye. Collagen shields, iontophoresis, and pumps, Ophthalmology., 98: 725-732.
147. Hill, J. M. (1991). Symposium on drug delivery. V. Ocular drug delivery; corneal collagen shields and ocular iontophoresis, Proc. Soc. Exp. biol. Med., 196: 365.
148. Burstein, N., and Anderson, J. A. (1985). Review: Corneal penetration and ocular bioavailability of drugs, J. Ocular Pharmacol., 1: 309-326.
149. Munjusha, M., and Majumdar, D. K. (1997). In vitro transcorneal penetration of ketorolac tromethamine from buffered and unbuffered aqueous ocular drops, Indian J. Exp. Biol., 35: 941-947.
150. DeSantis, L. M., and Schoenwald, R. D. (1978). Lack of influence of rabbit nectitating membrane on miosis effect of pilocarpine, J. Pharm. Sci., 67: 1189-1190.
151. Burstein, N. L., and Anderson, J. A. (1985). Review: Corneal penetration and ocular bioavailability of drugs, J. Ocular Pharmacol., 3: 309-326.
152. Klyce, S. D., and Beuerman, R. W. (1988). Structure and function of the cornea, in The Cornea(H. E. Kaufman, B. A. Barron, M. B. McDonald, S. R. Waltman, eds.), Churchill Livingstone, New York, pp. 3-54.
153. Pepose, J. S., and Ubels, J. L. (1992). The cornea, in Alder’s Physiology of the Eye(W. Hart, ed.), Mosby Year book, New York, pp. 29-70.
154. A. K. Mitra. Ophthalmic drug delivery. In: P. Tyle, ed. Drug Delivery Devices. New York: Marcel Dekker, 1988.